关注
Jeremy Force
Jeremy Force
在 duke.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
A Norden-Zfoni, J Desai, J Manola, P Beaudry, J Force, R Maki, ...
Clinical Cancer Research 13 (9), 2643-2650, 2007
2502007
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells …
P Beaudry, J Force, GN Naumov, A Wang, CH Baker, A Ryan, S Soker, ...
Clinical Cancer Research 11 (9), 3514-3522, 2005
2082005
The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in …
OM Fayanju, Y Ren, SM Thomas, RA Greenup, JK Plichta, ...
Annals of surgery 268 (4), 591-601, 2018
1762018
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve
I Celik, O Sürücü, C Dietz, JV Heymach, J Force, I Höschele, ...
Cancer research 65 (23), 11044-11050, 2005
1622005
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells
G Schuch, JV Heymach, M Nomi, M Machluf, J Force, A Atala, JP Eder Jr, ...
Cancer research 63 (23), 8345-8350, 2003
1472003
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin
GD Girnun, L Chen, J Silvaggi, R Drapkin, LR Chirieac, RF Padera, ...
Clinical cancer research 14 (20), 6478-6486, 2008
1022008
Mechanisms of therapeutic antitumor monoclonal antibodies
LC Tsao, J Force, ZC Hartman
Cancer research 81 (18), 4641-4651, 2021
1012021
Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database
CT Ong, BM Campbell, SM Thomas, RA Greenup, JK Plichta, ...
Annals of surgical oncology 25, 2249-2260, 2018
982018
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non–small-cell lung cancer receiving sorafenib
RJ Kelly, A Rajan, J Force, A Lopez-Chavez, C Keen, L Cao, Y Yu, ...
Clinical cancer research 17 (5), 1190-1199, 2011
852011
Checkpoint blockade strategies in the treatment of breast cancer: where we are and where we are heading
J Force, JHS Leal, HL McArthur
Current treatment options in oncology 20 (4), 35, 2019
572019
First-line treatment of metastatic melanoma: role of nivolumab
J Force, AKS Salama
ImmunoTargets and therapy, 1-10, 2017
422017
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence
CC Lin, NW Mabe, YT Lin, WH Yang, X Tang, L Hong, T Sun, J Force, ...
Cell Death & Differentiation 27 (7), 2234-2247, 2020
412020
Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and αPD-1 enable sustained antitumor responses against established HER2 breast cancer
EJ Crosby, CR Acharya, AF Haddad, CA Rabiola, G Lei, JP Wei, XY Yang, ...
Clinical Cancer Research 26 (17), 4670-4681, 2020
382020
Biomarkers of immune checkpoint blockade response in triple-negative breast cancer
J Isaacs, C Anders, H McArthur, J Force
Current treatment options in oncology 22, 1-15, 2021
362021
Nodular regenerative hyperplasia after treatment with trastuzumab emtansine
J Force, R Saxena, BP Schneider, AM Storniolo, GW Sledge Jr, ...
Journal of Clinical Oncology 34 (3), e9-e12, 2016
312016
APOBEC mutagenesis inhibits breast cancer growth through induction of T cell–mediated antitumor immune responses
AV DiMarco, X Qin, BJ McKinney, NMG Garcia, SC Van Alsten, ...
Cancer immunology research 10 (1), 70-86, 2022
292022
Novel cancer therapies and their association with diabetes
AI Shariff, S Syed, RA Shelby, J Force, JM Clarke, D D’Alessio, L Corsino
Journal of molecular endocrinology 62 (2), R187-R199, 2019
292019
Early stage HER2-positive breast cancers not achieving a pCR from neoadjuvant trastuzumab-or pertuzumab-based regimens have an immunosuppressive phenotype
J Force, LJ Howie, SE Abbott, R Bentley, PK Marcom, G Kimmick, ...
Clinical breast cancer 18 (5), 410-417, 2018
282018
Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients
OM Fayanju, Y Ren, RA Greenup, JK Plichta, LH Rosenberger, J Force, ...
Breast cancer research and treatment 180, 207-217, 2020
212020
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer
J Force, A Rajan, E Dombi, SM Steinberg, G Giaccone
Journal of Thoracic Oncology 6 (7), 1267-1273, 2011
212011
系统目前无法执行此操作,请稍后再试。
文章 1–20